摘要
吉西他滨(GEM)作为一种新型嘧啶类抗代谢剂,对多种实体瘤尤其是非小细胞肺癌、胰腺癌、乳腺癌、膀胱癌等具有独特的抗瘤活性。它在非小细胞肺癌和胰腺癌治疗中的地位已被确定,临床应用显示其不良反应轻微,耐受性好,近年来被广泛应用于乳腺癌,联合用药疗效好,且不良反应可控制,使用其单剂或含GEM联合方案救治晚期乳腺癌取得了令人注目的临床效果。本文对晚期乳腺癌患者使用GEM及联合方案治疗的疗效和安全性予以综述。
As a new miazines crystallose,gemcitabine has unique antineoplastic activity against many kinds of solid tumor,especially non-small cell lung cancer,pancreatic cancer and breast cancer.It has been confirmed that gemcitabine is effective in the treatment of non-small cell lung cancer and pancreatic cancer with slight adverse reactions and good tolerance in clinical application.For the past few years,gemcitabine was extensively used in breast cancer,and the efficacy could be good,adverse reactions could be controlled through combination treatments,especially for later stage breast carcinoma.This paper summarized the effects and safety of gemcitabine and gemcitabine combination treatment of later stage breast carcinoma.
出处
《医学综述》
2009年第21期3291-3293,共3页
Medical Recapitulate
关键词
乳腺癌
耐药
吉西他滨
Breast carcinoma
Resistance
Gemcitabine
